Spark Therapeutics (NASDAQ: ONCE) was up 9.21% in trading on Wednesday, July 5, 2017, closing at $65.56. $65 has been a resistance point in recent months. The company is scheduled to release interim data from its Phase I/II clinical trial for hemophilia B at the upcoming International Society on Thrombosis and Haemostasis 2017 Congress in Berlin. The company will make three presentations at the conference starting with the first on July 10. SPK-9001 is a gene therapy approach for hemophilia B using a bio-engineered AAV vector delivering a high-activity factor IX transgene.
